A new play­er joins the RNA edit­ing race on the heels of Eli Lil­ly's $1B-plus deal

4 years ago
Financing

As Delta takes con­trol, US re­sumes use of Lil­ly's Covid-19 mAb com­bo na­tion­wide

4 years ago
Coronavirus

Aim­ing to up­root the mar­ket for asth­ma at­tacks, As­traZeneca and Avil­lion tout two PhI­II wins for in­haled com­bo drug

4 years ago
R&D

Strug­gling Acor­da team brings out the axe — yet again — to chop away at costs as sales sput­ter

4 years ago
Pharma

Ex­clu­sive: Prison and multi­bil­lion dol­lar buy­outs lat­er, Sam Wak­sal is all in on the biotech game, with some big-name ...

4 years ago
People
Startups

Jen­nifer Doud­na's di­ag­nos­tic spin­out rais­es Mam­moth round as it ex­pands to ther­a­pies

4 years ago
Financing
Cell/Gene Tx

Io­n­is col­lab­o­ra­tor Flamin­go is ready to take flight with 3 an­ti­sense drugs in the clin­ic and mys­te­ri­ous RNA in its ...

4 years ago
Startups
Deals

A new clutch of biotech blue-chip­pers joins Ob­sid­i­an's quest to craft next-gen drugs with an 'on' switch

4 years ago
Financing
R&D

Medicx­i's mega-start­up Centes­sa rolls out first da­ta for he­mo­phil­ia drug with plans to charge ahead in­to piv­otal test

4 years ago
R&D

Af­ter get­ting their can­di­dates back from Eli Lil­ly, the old Der­mi­ra team is dash­ing for the clin­ic

4 years ago
Financing

Eli Lil­ly-backed Ly­cia fu­els up on VC cash in a dis­cov­ery dri­ve to­ward pro­tein degra­da­tion 2.0

4 years ago
Financing

The Tachi Ya­ma­da lega­cy tree con­tin­ues to grow with a new gene edit­ing biotech from Jim Wil­son

4 years ago
Financing
Startups

Hu­mani­gen crash­es as FDA shoots down its Covid-19 drug EUA

4 years ago
R&D
Coronavirus

A top pick in Paul Hud­son's cam­paign to re­vive the pipeline at Sanofi blows up in PhI­II

4 years ago
R&D

Ronald Crys­tal's Lex­eo Ther­a­peu­tics pulls in a $100M megaround just nine months af­ter launch

4 years ago
Financing

Eli Lil­ly bets on an RNA base edit­ing out­fit lever­ag­ing the body's own en­zymes to re­verse mu­ta­tions

4 years ago
Deals
Discovery

Top bio­phar­ma ex­ecs of­fer scare tac­tics and mixed mes­sages on drug pric­ing bills mak­ing their way to Capi­tol Hill

4 years ago
R&D
Pharma

A few months in­to his new role at At­tralus, ex-Pur­due chief Mark Tim­ney leads the biotech to a $116M round

4 years ago
People
Financing

Look­ing for fresh start fol­low­ing a Duchenne dis­as­ter, Cataba­sis re­brands; Huadong and In­sil­i­co team up in on­col­o­gy

4 years ago
News Briefing

Covid-19 roundup: Gates Foun­da­tion, Ex­sci­en­tia team up on pan­dem­ic an­tivi­ral dis­cov­ery pact; No­vavax opens tri­al for ...

4 years ago
Coronavirus

Months af­ter land­ing Cana­di­an site from gov­ern­ment, Re­silience an­nounces a big mR­NA part­ner

4 years ago
Deals
Manufacturing

One of Tachi's new­ly born lega­cy biotechs rais­es $135M and en­lists an A-list board to ad­vance late-stage vac­cine

4 years ago
Financing

Mod­er­na sur­faces as the first part­ner for Jim Wilson's rare dis­ease non­prof­it, do­nat­ing an mR­NA pro­gram at no cost

4 years ago
People
Pharma

As blue­bird plans its big split, rare dis­ease head An­drew Oben­shain re­cruits Iron­wood vet as CFO

4 years ago
People
First page Previous page 652653654655656657658 Next page Last page
A service from the Financial Times